By Chris Wack
PepGen Inc. shares were up 19%, to $6.17, after the company said it saw positive results from its completed trial of PGN-EDO51, its lead product candidate for the treatment of certain Duchenne Muscular Dystrophy patients.
The biotechnology company's Phase 1 HNV trial of PGN-EDO51 was a single ascending dose clinical trial evaluating the safety and tolerability of PGN-EDO51 in 32 healthy adult males. Oligonucleotide tissue concentration and exon skipping also were assessed.
The trial met its primary endpoint assessing the safety profile of PGN-EDO51 at pharmacologically relevant doses. PGN-EDO51 was generally well tolerated.
PepGen now plans to begin a Phase 2a multiple ascending dose clinical trial in DMD patients in the first half of 2023.
All participants completed the trial; there were no discontinuations. The majority of treatment-emergent adverse events were assessed as mild and resolved without any intervention. At 10 mg/kg, there were only Grade 1 adverse events.
The stock hit its 52-week low of $4.32 last Friday, and is down 48% in the last three months.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
September 28, 2022 10:00 ET (14:00 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.